Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03181841
Other study ID # PHA-16-D1AGO-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 8, 2017
Est. completion date December 20, 2017

Study information

Verified date November 2020
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Numerous psychiatric and neurodegenerative diseases like schizophrenia, dependency on drugs of abuse, depression and Parkinson's disease are related to motivational and cognitive deficits in value-based decision making, which frequently persist even after a successful pharmacological treatment. According to current neurobiologic models, cortical dopamine D1 receptors play a crucial role in taking value-based decisions. In this study, it will be investigated whether value-based decisions in healthy volunteers can be improved by stimulation of D1-receptors. For this purpose, a newly developed dopamine D1-agonist will be used, which selectively increases the activities of frontal D1- and D5-receptors. In this double-blind, randomized, placebo-controlled study, the effects of different single doses of PF-06412562, a not yet licensed D1-agonist, on value-based decision making will be compared with placebo. The use of different dosage strengths will allow to investigate a potential relationship between the extent of activity of the D1-receptor and its influence on behavioral indices. Therefore, four parallel groups will be investigated. Each participant takes in a single dose of either PF-06412562 in different doses or placebo. A screening exam will be carried out 1-3 weeks before the drug intake, and a follow-up examination will be carried out approx. 1 week after the drug intake. At all 3 visits in the study centre, several tests for the investigation of value-based decision making will be carried out.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date December 20, 2017
Est. primary completion date December 20, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Informed Consent as documented by signature on the informed consent form - Physically and psychiatrically healthy men and women - Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days for females and 90 days for males after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children. - Female subjects of non childbearing potential must meet at least one of the following criteria: - Have undergone a documented hysterectomy and/or bilateral oophorectomy; - Have medically confirmed ovarian failure or; - Achieved post menopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and have a serum follicle stimulating hormone (FSH) level confirming the post menopausal state. - All other female subjects (including females with tubal ligations and females that do NOT have a documented hysterectomy, bilateral oophorectomy and/or ovarian failure) will be considered to be of childbearing potential. - Aged 18-35 years - Negative pregnancy test (see exclusion criteria) - Normal or corrected-to-normal vision Exclusion Criteria (selected): - Pregnant female subjects; breastfeeding female subjects - considered to be healthy based on an extensive pre-study screening including anamnesis, physical examination, laboratory investigations, vital signs, ECG, etc.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PF-06412562
double-blind oral intake of single doses of the aforementioned drug or placebo
Placebo
double-blind oral intake of single doses of the aforementioned drug or placebo

Locations

Country Name City State
Switzerland University Hospital Zurich, Dept. of Clinical Pharmacology and Toxicology Zurich

Sponsors (2)

Lead Sponsor Collaborator
University of Zurich Pfizer

Country where clinical trial is conducted

Switzerland, 

References & Publications (2)

Soutschek A, Gvozdanovic G, Kozak R, Duvvuri S, de Martinis N, Harel B, Gray DL, Fehr E, Jetter A, Tobler PN. Dopaminergic D(1) Receptor Stimulation Affects Effort and Risk Preferences. Biol Psychiatry. 2020 Apr 1;87(7):678-685. doi: 10.1016/j.biopsych.20 — View Citation

Soutschek A, Kozak R, de Martinis N, Howe W, Burke CJ, Fehr E, Jetter A, Tobler PN. Activation of D1 receptors affects human reactivity and flexibility to valued cues. Neuropsychopharmacology. 2020 Apr;45(5):780-785. doi: 10.1038/s41386-020-0617-z. Epub 2 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Plasma concentrations of PF-06412562 blood sampling 4 hours and 8 hours after the study drug intake.
Primary Change from baseline in a delay discounting task. This validated computer-based decision-making test will be filled in by each participant at three time points during the study: 1-3 weeks before, 5 hours after, and approx. 1 week after a single oral intake of 1 out of 3 possible doses of PF-06412562, or matching placebo. 1-3 weeks before (= baseline), 5 hours after, and approx. 1 week after drug intake.
Primary Change from baseline in a risk discounting task. This validated computer-based decision-making test will be filled in by each participant at three time points during the study: 1-3 weeks before, 5 hours after, and approx. 1 week after a single oral intake of 1 out of 3 possible doses of PF-06412562, or matching placebo. It will be carried out after the test for outcome 1. 1-3 weeks before (= baseline), 5 hours after, and approx. 1 week after drug intake.
Primary Effect of PF-06412562 on an effort discounting task (compared to placebo). This validated computer-based decision-making test will be completed by each participant 5 hours after a single oral intake of 1 out of 3 possible doses of PF-06412562, or matching placebo and after having completed the tests for outcome 1 and 2. 5 hours after drug intake.
Primary Effect of PF-06412562 on the Pavlovian to instrumental transfer task (compared to placebo). This validated computer-based decision-making task tests Pavlovian acquisition and transfer. It will be carried out by each participant immediately after the test in outcome 3. 5 hours after drug intake.
Primary Effect of PF-06412562 on an exploration / exploitation task (compared to placebo). This validated computer-based decision-making task tests different aspects of value-based decision making. It will be carried out by each participant immediately after the test in outcome 4. 5 hours after drug intake.
Primary Effect of PF-06412562 on a probabilistic reversal learning task (compared to placebo). This validated computer-based decision-making task tests different aspects of value-based decision making. It will be carried out by each participant immediately after the test in outcome 5. 5 hours after drug intake.
Secondary Incidence of treatment-emergent adverse events (safety and tolerability of PF-06412562) continuous assessment of adverse events by non-leading questions, repeated safety laboratory tests, repeated ECGs, repeated control of vital parameters. throughout the study and up to 1 week after study drug intake.
See also
  Status Clinical Trial Phase
Completed NCT01799291 - Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder N/A
Recruiting NCT03886025 - Combined Anodal Transcranial Direct Current Stimulation (tDCS) and Cognitive Training and Decision-making N/A
Completed NCT03185715 - Oocyte Recipient's Decision in the Number of Embryos to be Transferred N/A
Completed NCT05974943 - The Effect of Problem Solving and Decision Making Training Given to Nurses Managers N/A
Terminated NCT05024903 - A Novel E-health Platform Phase 2/Phase 3
Completed NCT04509063 - Investigating Public Enthusiasm for Mammography Screening in Denmark N/A
Completed NCT03762239 - Effect of Air Pollution on the Cognitive Function of Adolescents N/A
Not yet recruiting NCT06081842 - Strengthening Contraceptive Counseling Services: Research Protocol for a Multi-phase Complex Intervention in Pakistan and Nigeria N/A
Completed NCT01190488 - Feasibility Of An Advanced Care Decision Aid Among Patients And Physicians_Matlock N/A
Active, not recruiting NCT04466865 - A Communication Tool to Assist Older Adults Facing Dialysis Choices N/A
Active, not recruiting NCT06046625 - Needs and Preferences of Patients With Head-neck Cutaneous SCC
Recruiting NCT03554694 - Gut-brain Axis, Brain Function, and Behaviour. N/A
Recruiting NCT05201534 - Interventions in Mathematics and Cognitive Skills N/A
Completed NCT04000802 - Evaluation of the Decision-making During Multidisciplinary Meetings for Digestive Cancers
Completed NCT04034979 - Evaluation of a Decision Aid About Life-sustaining Therapies N/A
Active, not recruiting NCT05173922 - "Safety in Dementia": An Online Caregiver Intervention N/A
Withdrawn NCT01098864 - Transcranial Magnetic Stimulation of the Prefrontal Cortex: Effects on Risky Decision Making and Temporal Discounting. N/A
Recruiting NCT05364801 - Impact of Anxiety on the Decision-making Processes of Anesthesiologists
Completed NCT06355999 - Levari Exp.20: 2D - Partial Feedback N/A
Enrolling by invitation NCT05390411 - Seeking Objectivity in Allocation of Advanced Heart Failure (SOCIAL HF) Therapies Trial N/A